Post-thaw dimethyl sulfoxide reduction in autologous peripheral blood progenitor cell suspensions
Background and objectives: Dimethyl sulfoxide has become the most common cryoprotectant used for cryopreservation of hematopoietic progenitor cells because of its efficiency, regardless of its potentially toxic side effects. Its application is considered safe, provided that the daily dose administer...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-10-01
|
| Series: | Hematology, Transfusion and Cell Therapy |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2531137925002330 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849222566306119680 |
|---|---|
| author | Miroslava Jandová Pavel Měřička Jiří Gregor Miriam Lánská Aleš Bezrouk Dana Čížková Jakub Radocha |
| author_facet | Miroslava Jandová Pavel Měřička Jiří Gregor Miriam Lánská Aleš Bezrouk Dana Čížková Jakub Radocha |
| author_sort | Miroslava Jandová |
| collection | DOAJ |
| description | Background and objectives: Dimethyl sulfoxide has become the most common cryoprotectant used for cryopreservation of hematopoietic progenitor cells because of its efficiency, regardless of its potentially toxic side effects. Its application is considered safe, provided that the daily dose administered does not exceed 1 gram per kilogram of patient weight. Indications for its reduction after thawing are limited to patients with high risk of malignant arrhythmia and those with severely impaired renal function. However, dimethyl sulfoxide reduction can lead to the loss of viable progenitors. Methods: A retrospective study of viable hematopoietic progenitor cell recovery after dimethyl sulfoxide reduction was performed with 13 patients (nine men, four women) with secondary amyloidosis in multiple myeloma (n = 9), primary amyloid light chain amyloidosis (n = 3), or severe adverse reaction at the beginning of the hematopoietic progenitor cell concentrate infusion (n = 1). The Wilcoxon signed-rank test was used. Results: The results of the dimethyl sulfoxide reduction process showed a high recovery of viable nucleated cells (median: 120.85 %), and of viable mononuclear cells (median: 104.53 %). There was a significant decrease in total number of viable CD34+ cells in comparison with data obtained after original collection (median: 51.49 %). No significant decrease in colony-forming unit capacity was observed after dimethyl sulfoxide reduction (median: 93.37 %). Conclusion: The dimethyl sulfoxide removal process and total process recoveries revealed considerable individual variability. To minimize the risk of prolonged engraftment or non-engraftment, it is important to apply this process only to high-risk patients. |
| format | Article |
| id | doaj-art-62db6d1de08045d997ac0b95e6250855 |
| institution | Kabale University |
| issn | 2531-1379 |
| language | English |
| publishDate | 2025-10-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Hematology, Transfusion and Cell Therapy |
| spelling | doaj-art-62db6d1de08045d997ac0b95e62508552025-08-26T04:14:28ZengElsevierHematology, Transfusion and Cell Therapy2531-13792025-10-0147410396510.1016/j.htct.2025.103965Post-thaw dimethyl sulfoxide reduction in autologous peripheral blood progenitor cell suspensionsMiroslava Jandová0Pavel Měřička1Jiří Gregor2Miriam Lánská3Aleš Bezrouk4Dana Čížková5Jakub Radocha6University Hospital Hradec Králové, Tissue Bank, Czechia; Charles University, Faculty of Medicine in Hradec Králové, Department of Histology and Embryology, Czechia; Corresponding author at: Tissue Bank, University Hospital Hradec Králové, Sokolská 585, 500 05 Hradec Králové – Nový Hradec Králové, Czechia.University Hospital Hradec Králové, Tissue Bank, CzechiaUniversity Hospital Hradec Králové, Tissue Bank, CzechiaUniversity Hospital Hradec Králové, 4th Department of Internal Medicine - Hematology Czech Republic, CzechiaCharles University, Faculty of Medicine in Hradec Králové, Department of Medical Biophysics, CzechiaCharles University, Faculty of Medicine in Hradec Králové, Department of Histology and Embryology, CzechiaUniversity Hospital Hradec Králové, 4th Department of Internal Medicine - Hematology Czech Republic, CzechiaBackground and objectives: Dimethyl sulfoxide has become the most common cryoprotectant used for cryopreservation of hematopoietic progenitor cells because of its efficiency, regardless of its potentially toxic side effects. Its application is considered safe, provided that the daily dose administered does not exceed 1 gram per kilogram of patient weight. Indications for its reduction after thawing are limited to patients with high risk of malignant arrhythmia and those with severely impaired renal function. However, dimethyl sulfoxide reduction can lead to the loss of viable progenitors. Methods: A retrospective study of viable hematopoietic progenitor cell recovery after dimethyl sulfoxide reduction was performed with 13 patients (nine men, four women) with secondary amyloidosis in multiple myeloma (n = 9), primary amyloid light chain amyloidosis (n = 3), or severe adverse reaction at the beginning of the hematopoietic progenitor cell concentrate infusion (n = 1). The Wilcoxon signed-rank test was used. Results: The results of the dimethyl sulfoxide reduction process showed a high recovery of viable nucleated cells (median: 120.85 %), and of viable mononuclear cells (median: 104.53 %). There was a significant decrease in total number of viable CD34+ cells in comparison with data obtained after original collection (median: 51.49 %). No significant decrease in colony-forming unit capacity was observed after dimethyl sulfoxide reduction (median: 93.37 %). Conclusion: The dimethyl sulfoxide removal process and total process recoveries revealed considerable individual variability. To minimize the risk of prolonged engraftment or non-engraftment, it is important to apply this process only to high-risk patients.http://www.sciencedirect.com/science/article/pii/S2531137925002330Peripheral blood progenitor cellsCryopreservationDMSO reductionAmyloidosisCell recovery |
| spellingShingle | Miroslava Jandová Pavel Měřička Jiří Gregor Miriam Lánská Aleš Bezrouk Dana Čížková Jakub Radocha Post-thaw dimethyl sulfoxide reduction in autologous peripheral blood progenitor cell suspensions Hematology, Transfusion and Cell Therapy Peripheral blood progenitor cells Cryopreservation DMSO reduction Amyloidosis Cell recovery |
| title | Post-thaw dimethyl sulfoxide reduction in autologous peripheral blood progenitor cell suspensions |
| title_full | Post-thaw dimethyl sulfoxide reduction in autologous peripheral blood progenitor cell suspensions |
| title_fullStr | Post-thaw dimethyl sulfoxide reduction in autologous peripheral blood progenitor cell suspensions |
| title_full_unstemmed | Post-thaw dimethyl sulfoxide reduction in autologous peripheral blood progenitor cell suspensions |
| title_short | Post-thaw dimethyl sulfoxide reduction in autologous peripheral blood progenitor cell suspensions |
| title_sort | post thaw dimethyl sulfoxide reduction in autologous peripheral blood progenitor cell suspensions |
| topic | Peripheral blood progenitor cells Cryopreservation DMSO reduction Amyloidosis Cell recovery |
| url | http://www.sciencedirect.com/science/article/pii/S2531137925002330 |
| work_keys_str_mv | AT miroslavajandova postthawdimethylsulfoxidereductioninautologousperipheralbloodprogenitorcellsuspensions AT pavelmericka postthawdimethylsulfoxidereductioninautologousperipheralbloodprogenitorcellsuspensions AT jirigregor postthawdimethylsulfoxidereductioninautologousperipheralbloodprogenitorcellsuspensions AT miriamlanska postthawdimethylsulfoxidereductioninautologousperipheralbloodprogenitorcellsuspensions AT alesbezrouk postthawdimethylsulfoxidereductioninautologousperipheralbloodprogenitorcellsuspensions AT danacizkova postthawdimethylsulfoxidereductioninautologousperipheralbloodprogenitorcellsuspensions AT jakubradocha postthawdimethylsulfoxidereductioninautologousperipheralbloodprogenitorcellsuspensions |